Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

A Biden spokeswoman confirmed the former president finished several weeks of radiation therapy treatment Monday.

Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final ...

Biden announced in May that he had an advanced stage of prostate cancer that has metastasized, or spread, to his bones, ...

It is not unusual for advanced prostate cancer to become resistant to treatment. Of these resistant cases, some progress to a ...